EDAP TMS SA annual report, Q4 FY2023

EDAP TMS S.A. — Form 20-F Summary

Reporting period: Fiscal year ended December 31, 2023. This is an annual report, not a standalone fourth-quarter filing; the filing text does not provide separate Q4 results. Filed March 28, 2024. Financial statements are prepared under U.S. GAAP and reported in euros.

Business context

EDAP develops, manufactures and distributes minimally invasive medical technologies, principally for urology. Its divisions are HIFU (Focal One robotic ultrasound), ESWL (lithotripsy equipment and services) and Distribution (third-party devices, including ExactVu micro-ultrasound and lasers). Strategy centers on expanding Focal One adoption in the U.S. and developing HIFU applications beyond prostate disease.

Financial and operating results

Metric20232022
Revenue€60.4 million€55.1 million
Gross profit / margin€24.4 million / 40.4%€24.2 million / 43.9%
Operating loss€19.8 million€4.3 million
Net loss€21.2 million€2.9 million
Operating cash flow(€14.7 million)(€3.0 million)
Capital expenditures / investing cash flow€4.3 million outflow€2.4 million outflow
Cash and cash equivalents at year-end€43.5 million€63.1 million
  • Revenue by division: HIFU €20.6 million, up 31.7%; ESWL €9.9 million, down 14.3%; Distribution €29.9 million, up 7.2%.
  • HIFU sold 21 Focal One systems (15 in the U.S.), versus 15 in 2022. Treatment-driven revenue increased 30% to €9.1 million.
  • Cost of sales rose 16.5% to €36.0 million, faster than revenue, reducing gross margin by 3.5 percentage points.
  • Operating expenses increased 55.4% to €44.2 million, including higher U.S. HIFU sales and marketing and R&D spending, share-based compensation, and €3.4 million of non-recurring leadership succession costs.
  • Net financial income was €1.1 million, while foreign-exchange losses were €1.8 million; 2022 had a €1.9 million foreign-exchange gain.
  • Cash declined €19.7 million during 2023. Operating cash use reflected the net loss and a €2.9 million working-capital increase, including higher inventory and receivables. No off-balance-sheet financing was reported.
  • At year-end, total assets were €91.5 million, total liabilities €34.6 million and shareholders’ equity €56.9 million. Borrowings were €2.5 million short-term and €3.6 million long-term; finance and operating lease obligations totaled about €2.4 million.

Material changes, outlook and commentary

  • Revenue grew 9.6%, but operating and net losses widened substantially as the company increased U.S. commercial, clinical and R&D investment. The company reported operating losses in 2021, 2022 and 2023.
  • Management expects R&D spending to rise to 11.9% of revenue in 2024 and expects selling, marketing and G&A expenses to increase as U.S. HIFU expansion continues. No specific revenue or profitability target is provided.
  • CMS maintained HIFU at APC Level 6 for 2024. The company cites average Medicare hospital reimbursement of $8,777 per procedure and physician payment of about $956 in a facility setting.
  • French health authorities issued a favorable opinion in late 2023 recommending HIFU coverage for certain prostate cancer treatments; the reimbursement rate and implementation timing remained to be determined.
  • On March 4, 2024, after year-end, the FDA granted Focal One Breakthrough Device designation for deep infiltrating endometriosis. This designation is not itself marketing approval.
  • The company identifies inflation and component-price pressures, including a substantial price increase from a key HIFU component supplier, as threats to margins. It relies on a single principal manufacturing site and some single-source components.
  • Other material risks include lengthy and variable hospital purchasing cycles, reimbursement and regulatory uncertainty, competition, foreign-exchange exposure, and dependence on distributors. The company had no outstanding foreign-exchange hedges at year-end.
  • Liquidity is supported by year-end cash, but management notes operating cash-flow volatility and potential need for financing if growth, spending or demand develops differently than expected. The company does not intend to pay dividends in the foreseeable future.

Controls, audit and contingencies

  • KPMG issued an unqualified opinion on the consolidated financial statements, but an adverse opinion on internal control over financial reporting. A material weakness remained at the U.S. subsidiary in controls over recording third-party vendor invoices. Management said it did not cause a material misstatement or require a restatement and described planned staffing and IT remediation.
  • The filing identifies revenue recognition for distinct performance obligations in multi-element device arrangements as a critical audit matter.
  • The company reported no outstanding legal proceedings. Disclosed commitments include debt and lease payments; standard product warranties are its stated contingencies.

Important facts for investors to verify

  • Whether U.S. Focal One placements and procedure volumes grow enough to offset rising commercial and R&D costs and improve operating losses and cash burn.
  • Whether gross margin recovers despite inflation, product mix and the higher cost of key HIFU components.
  • Whether the remaining U.S. vendor-invoice control weakness is remediated, and whether auditor assessments change.
  • Whether the favorable French HIFU coverage recommendation results in a reimbursement rate and effective date, and how private-payer coverage develops in the U.S.
  • Whether the endometriosis clinical and regulatory pathway advances beyond Breakthrough Device designation, and whether Japan approval efforts progress.
  • The pace of cash consumption, working-capital needs, debt repayments and any future equity financing or dilution.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.